Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02164565
Other study ID # 104-12-EMC
Secondary ID
Status Withdrawn
Phase Phase 4
First received May 29, 2014
Last updated August 13, 2017
Start date June 2014
Est. completion date March 2015

Study information

Verified date August 2017
Source HaEmek Medical Center, Israel
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The use of Tranexamic Acid (TXA) intravenously, to Reduce Blood Loss in proximal femur surgery.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2015
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria:

- Patients over 60, who came to the orthopedic department for proximal femur fracture surgery

- Sound judgment

Exclusion Criteria:

- Known hypersensitivity to Tranexamic Acid or component solution provided

- Subarachnoid hemorrhage

- Acquired color blindness

- Myocardial infarction in 12 months before admission

- Unstable angina

- Known clotting disorders (Thromboembolic disease in the past, elongated PT and PTT, hypercoagulability),

- Kidney or liver failure

- Another situation prostate resection , pathologic fractures according to anamnesis or by imaging

- Oncology patients

- Patients on anticoagulation

- Patients undergoing vascular intervention ( coronary or peripheral ), which was inserted Supporter requires a Dual antiplatelet therapy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tranexamic Acid (TXA) treatment
Tranexamic Acid (TXA) treatment
control grup: without Tranexamic Acid (TXA) treatment.
control grup: without Tranexamic Acid (TXA) treatment.

Locations

Country Name City State
Israel Orthopedic Department, HaEmek Medical Center Afula

Sponsors (1)

Lead Sponsor Collaborator
HaEmek Medical Center, Israel

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of blood loss in ml. Hbloss=BV X (Hbi - Hbe) X 0.001 + Hbt Hbi - hemoglobin level before the surgery ) gram X liter-1(. Hbe - hemoglobin level 3 days after the surgery ( gram X liter-1). Hbt - The amount of hemoglobin that was given in the blood transfusion (gram). Hbloss - Change of hemoglobin loss.
After calculating the amount of loss of hemoglobin, the volume of blood lost can be found:
Blood loss = 1000 X Hbloss/ Hbi
Evaluation of blood loss will be through:
1. Comparing hemoglobin level before and after surgery and calculation of quantitative Change of hemoglobin loss.
2 .Registration evaluating blood loss at the end of surgery 3. Collecting and recording blood drain. 4. Tracking Blood Transfusion. Of course we collect the data: assessment of bleeding in the analysis, the number of blood units given, the amount of blood collected drain
up to 13 months